Replies to post #251112 on Avid Bioservices Inc (CDMO)

[exwannabe]

I do hope Peregrine can take another crack at pancreatic cancer. It is such a nasty disease.

The problem is that they would have to start over with an Abraxane combo. And that was a cost they did not see justified.

The Abraxane data was clearly good, despite Nuke's diss'ing of it. The 2 year survival (from his linked package insert) was 10% vs 6%. One can say that does not matter, but it is almost doubling ones chances of living 2 years (longer data was to thin to be meaningful).

[Nuke's survival numbers were math flawed. (N-E)/N is not even close to survival percent when the censor rate is high].

As a total aside, it might be a better target for BBs anyway. Pancreatic is surrounded by a very dense tissue (stroma) that makes penetration by drugs difficult. BB's are much smaller.